Biotech · Private company · Seattle, WA, US
Alpine Immune Sciences, Inc.
SEC CIK 0001626199
Track this companyFree. Adds Alpine Immune Sciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- PovetaciceptPhase 2 · Lupus NephritisClinicalTrials.gov · fetched Nov 12, 2026
- ALPN-101Phase 1 · Graft Vs Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ALPN-202Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumab KEYTRUDA®Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 15, 2023ClinicalTrials.gov NCT05732402 · fetched Nov 12, 2026
- ALPN-202 With PD-1 Inhibition in Advanced MalignanciesPHASE1 · TERMINATED · started Jun 22, 2021ClinicalTrials.gov NCT04920383 · fetched Nov 12, 2026
- An Open-label Study of ALPN-202 in Subjects With Advanced MalignanciesPHASE1 · TERMINATED · started Jun 2, 2020ClinicalTrials.gov NCT04186637 · fetched Nov 12, 2026
- ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHDPHASE1 · TERMINATED · started May 11, 2020ClinicalTrials.gov NCT04227938 · fetched Nov 12, 2026